STAAR Surgical Q1 Sales Up 119% Post-Alcon

STAAR Surgical posted Q1 GAAP EPS $0.10, net sales $93.5 million, a 119.6% YoY increase, beating estimates.
Stock rose to $33, surpassing Alcon’s final $30.75 per‑share buyout offer after shareholders rejected the merger on Jan 6 2026.
Operating income turned positive to $8 million and adjusted EBITDA to $24.4 million, versus losses of $57.4 million and $26.3 million a year earlier.
China net sales $47.4 million drove recovery, while U.S. sales exceeded $6 million, up 22% YoY amid declining LASIK volumes.